Internal Medicine Doctors in Brandon, VT Accepting Medicare
2 Internal Medicine doctors found. Showing 1 - 2
 John F Dick Ii, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 420 Grove St, Brandon, VT 05733 Phone: 802-247-6305 Fax: 802-247-6040 |
Dr. Gavin L Noble, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 61 Court Dr, Brandon, VT 05733 Phone: 802-382-3443 |
News Archive
FDA should apply equal rigor in assessing food claims and drug approvals, says new report
The U.S. Food and Drug Administration should apply the same rigor to evaluating the science behind claims of foods' and nutritional supplements' health benefits as it devotes to assessing medication and medical technology approvals, says a new report from the Institute of Medicine.
Silence strengthens RNAi IP portfolio with issuance of key patent in structural modification technology
Silence Therapeutics plc announces the issuance of United States patent 7,750,144, titled Methods and Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of producing double stranded (RNAi) agents having decreased off-target silencing activity through certain structural modifications. The ability to minimize the off-target effects of RNAi therapeutics is critical for controlling unwanted cellular activity and/or potential safety concerns.
Common diabetes therapies may increase cancer risk, but more research needed
The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk.
DNA methylation may influence the effects of aspirin in patients with breast cancer
Women with a particular DNA feature may live longer if they take aspirin even before they are diagnosed with breast cancer, a new study found.
FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness
Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced it has been granted Food and Drug Administration conditional Investigational Device Exemption approval to evaluate the safety and effectiveness of its CorPath® 200 System in delivering and manipulating coronary guidewires and stent/balloon systems in percutaneous coronary interventions procedures.
› Verified 3 days ago